Review
Nature Reviews Cancer 4, 937-947 (December 2004) | doi:10.1038/nrc1503
Focus on: kinases
Targeting the mitogen-activated protein kinase cascade to treat cancer
Judith S. Sebolt-Leopold1 & Roman Herrera1 About the authors
Abstract
The RAS–mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?
- View At a Glance
Author affiliations
- Molecular Sciences and Technologies, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
Correspondence to: Judith S. Sebolt-Leopold1 Email: Judith.Leopold@pfizer.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
MEK Wars, a new front in the battle against cancerNature Medicine News and Views (01 Jul 1999)
RESEARCH
BRAF mutation predicts sensitivity to MEK inhibitionNature Letters to Editor (19 Jan 2006)
See all 44 matches for Research